// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























45280 Abstracts

Work of breathing at different levels of volume-targeted ventilation in infants with congenital diaphragmatic hernia

Katie Hunt - European Respiratory Society (ERS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Congenital diaphragmatic hernia

Epoch

Repeatabillity of PExA SPA and albumin as small airways dysfunction candidate biomarkers in Asthma.

Marcia Soares - European Respiratory Society (ERS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

N/A

U-BIOPRED accessible handprint: combining omics platforms to identify stable asthma subphenotypes

Bertrand De Meulder - European Respiratory Society (ERS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

N/A

Computational modelling of oxygen insufflation during apnoea in obesity.

Marianna Laviola - European Respiratory Society (ERS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Tuberculosis

N/A

A comparison of outcomes from a regional Mesothelioma MDT against the National Lung Cancer Audit (NLCA) Mesothelioma standards

Maryam Ahmed - European Respiratory Society (ERS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Mesothelioma

N/A

Prevalence of inducible laryngeal obstruction (ILO) in unexplained chronic cough (UCC)

Simon Gray - European Respiratory Society (ERS) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Effect of prior year pulmonary exacerbation (PE) frequency on response to ARD-3150 in patients with non-cystic fibrosis bronchiectasis (NCFB) chronically infected with Pseudomonas aeruginosa (PA)

James D. Chalmers - European Respiratory Society (ERS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Cystic Fibrosis

ARD-3150

Long term respiratory and developmental outcomes of children with absent pulmonary valve syndrome

Elizabeth Brettle - European Respiratory Society (ERS) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

A single-centre, placebo-controlled, double-blinded, randomized, cross-over study of Iloprost in patients with Eisenmenger syndrome

Heba Nashat - European Respiratory Society (ERS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Eisenmenger syndrome

Iloprost

Patient attitudes toward a handheld non-invasive ventilator to relieve breathlessness.

Nicholas Lane - European Respiratory Society (ERS) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Spot Marching Exercise for home-based pulmonary rehabilitation in COPD: physical performance and quality of life

Chulee Jones - European Respiratory Society (ERS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

N/A

Steroid-resistant inflammation in a mouse model of severe asthma is not inhibited by the combination of theophylline and budesonide

Vince Russell - European Respiratory Society (ERS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

Theophylline

The cost benefit of initiating domiciliary Non-invasive Ventilation (NIV) as an outpatient is accompanied by good clinical outcomes for hypercapnic Chronic Obstructive Pulmonary Disease (COPD) patients

Charlotte Tai - European Respiratory Society (ERS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

N/A

Efficacy and safety profile of xanthines in COPD: a network meta-analysis

Mario Cazzola - European Respiratory Society (ERS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

Aminophylline Injection

Risk assessment in pulmonary arterial hypertension (PAH): Insights from the GRIPHON study

Olivier Sitbon - European Respiratory Society (ERS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Pulmonary arterial hypertension

Prostacyclin

Objective characterisation of difficult asthma in the WATCH study

Anna Freeman - European Respiratory Society (ERS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

N/A

Validation of breathing frequency algorithms in impedance pneumography

Carol Smyth - European Respiratory Society (ERS) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Fostamatinib for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia (wAIHA): A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Global Study

Nichola Cooper - American Society of Hematology (ASH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Chronic Lymphocytic Leukemia

Fostamatinib

C3 Inhibition with Pegcetacoplan in Patients with Paroxysmal Nocturnal Hemoglobinuria: Results from the Paddock and Palomino Trials

Raymond S Wong - American Society of Hematology (ASH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Paroxysmal nocturnal hemoglobinuria

Eculizumab

Management of Meningococcal Disease Risk in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) on Complement Inhibitors: 18 Years’ Experience from the UK National PNH Service in Leeds

Louise Arnold - American Society of Hematology (ASH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Paroxysmal nocturnal hemoglobinuria

N/A

Copyright © 2026. QuantiNova All rights reserved